Tag Archives: BIO International Convention

Expanding Access to Orphan Drugs

Orphan Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not always the case. In the field of blood-plasma proteins, therapies to treat hemophilia, alpha-1 deficiency and primary immune deficiencies have multiple innovator versions in a therapeutic class. Often one product in the class has received an orphan designation and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Opening Up Innovation

Cancer

Open Innovation has become a major theme in the life sciences over the last couple of years. Most of the attention has focused on initiatives where big pharma offers access to non-core assets to outside researchers in the hope that they will develop them successfully or form collaborations. In Sweden, AstraZeneca have followed this path, but interest in the concept has spread further down the discovery chain, generating creative initiatives from universities, tech transfer organizations, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Our Health Care Ecosystem

Meekers

There are currently 907 drugs and vaccines targeting more than 100 diseases in development by U.S. biopharmaceutical companies. It is the first step on a path toward bringing much needed treatments to patients. However, with the current focus on the cost of health care, regulatory approval is not the final hurdle. Increasingly, the ability of patients to access new therapies is determined by those who pay for the treatments. Skyrocketing development costs, concerns about the Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Legislative Hopes, Fears

PNNL Research Scientist Heather Brown

Biotechnology advances are poised now more than ever to help policymakers achieve their goals of supporting innovation in health care, renewable energy, and green technologies. How can they help us? Here are our six hopes (and one big concern) for the term ahead. HOPE 1: Cultivate an atmosphere for patient access to our products While the Congress considers finding savings, do it in a way that does not threaten patient access to drug products by Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , ,

Session Summary: What Every CEO Must Know About IP In Biotech

Biotech Boot Camp

On Sunday, April 21st, 2013, I attended a standing room only session titled, “What Every CEO Must Know About IP In Biotech”, part of Day One of Entrepreneurship Boot Camp. Kathryn Doyle, Ph.D., J.D., of Riverside Law and Stephan Sammut of the Wharton School spoke about changing patent laws and what they mean for biotech companies. Concepts and tips discussed included: How to develop a patent strategy when developing a product you’re trying to commercialize When Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,